Effects of heparin coating of cardiopulmonary bypass circuits on in vitro oxygen free radical production during coronary bypass surgery.
During cardiopulmonary bypass (CPB) oxygen free radicals (OFR) are formed, which can mediate reactions damaging tissue components. Blood contact with artificial surfaces during CPB leads to an activation of leukocytes, which are one of the sources of the OFR. Heparin coating of the CPB circuit reduces granulocyte activation. In the present study, the heparin-coated circuits with noncoated cardiotomy reservoirs (Group HC) were compared with noncoated, otherwise similar CPB sets (Group C). In each group, 8 patients were operated on for coronary revascularization. The release of granulocyte granule proteins myeloperoxidase (MPO) and lactoferrin (LF) was evaluated. Production of OFR in the whole blood and in the granulocyte suspension were measured by chemiluminescence (CL). In both groups the whole blood CL declined during CPB. The whole blood CL induced by serum-opsonized zymosan, when enhanced by luminol, was significantly lower in Group HC at 45 min after CPB start (68 +/- 6% of initial values in Group HC vs. 87 +/- 6% in Group C, mean +/- SEM) and 30 min after protaminization (54 +/- 6% of initial values in Group HC vs. 72 +/- 6% in Group C, mean +/- SEM), and CL was significantly higher in Group HC at CPB end (83 +/- 5% of initial values in Group HC vs. 67 +/- 5% in Group C, mean +/- SEM) when enhanced by lucigenin. CL of isolated granulocytes showed no significant differences between the groups. Release of MPO at CPB end and of LF 45 min after start of CPB and at CPB end were significantly lower in the heparin-coated CPB circuits.
Bozdayi
M
M
Department of Clinical Chemistry, University Hospital, Uppsala, Sweden.
Borowiec
J
J
Nilsson
L
L
Venge
P
P
Thelin
S
S
Hansson
H E
HE
D000328:Adult; D000704:Analysis of Variance; D002315:Cardiopulmonary Bypass / Q000592:standards*; D001026:Coronary Artery Bypass; D005260:Female; D005609:Free Radicals; D006098:Granulocytes / Q000201:enzymology; D006493:Heparin / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007431:Intraoperative Complications / Q000517:prevention & control; D007781:Lactoferrin / Q000378:metabolism; D007958:Leukocyte Count; D008163:Luminescent Measurements; D008213:Lymphocyte Activation; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000378:metabolism; D009195:Peroxidase / Q000378:metabolism; D011182:Postoperative Care; D011183:Postoperative Complications / Q000517:prevention & control; D017382:Reactive Oxygen Species
D005609:Free Radicals; D017382:Reactive Oxygen Species; D006493:Heparin; D009195:Peroxidase; D007781:Lactoferrin